# RASolute 305 (NCT07621718)

> Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07621718
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma
- Interventions: Zoldonrasib; Placebo; Oxaliplatin; Leucovorin (Calcium Folinate); 5-Fluorouracil; Irinotecan; Gemcitabine (GEM); Nab-paclitaxel
- Enrollment: 670
- Primary outcome: Progression free survival (PFS)
- Primary outcome: Overall survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 11
- YouTube: 3
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=rasolute-305-nct07621718

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07621718", "email": "<work email>"}; the inbox owner confirms by the emailed link.